Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Mar;63(3):395-400.
doi: 10.1002/ana.21363.

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

Amit Bar-Or  1 , Peter A J Calabresi, Douglas Arnold, Clyde Markowitz, Stuart Shafer, Lloyd H Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J Fox, Michael Panzara, Neena Sarkar, Sunil Agarwal, Craig H Smith
Affiliations
Clinical Trial

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

Amit Bar-Or et al. Ann Neurol. 2008 Mar.

Erratum in

  • Ann Neurol. 2008 Jun;63(6):803. Arnlod, Douglas [corrected to Arnold, Douglas]

Abstract

We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted; events were limited to mild-to-moderate infusion-associated events, which tended to decrease with subsequent infusions. Infections were also mild or moderate, and none led to withdrawal. Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

Substances

LinkOut - more resources